Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or reality?

European Journal of Clinical Pharmacology

Volumn 65, Issue 10, 2009, Pages 963-970

  Kefalakes, Helenie ^a   Stylianides, Theodoros J ^a   Amanakis, George ^a   Kolios, George ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

COX 1; COX 2; COX 2 inhibitors; Coxibs; Inflammatory bowel diseases; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; STEROID;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BIBLIOGRAPHIC DATABASE; BLEEDING; COLITIS; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENTERITIS; HUMAN; ILEITIS; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LOW DRUG DOSE; MEDLINE; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RELAPSE; REVIEW; SMALL INTESTINE DISEASE; ULCER; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATORY BOWEL DISEASES; RECURRENCE;

EID: 70349232206     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0719-3     Document Type: Review

References (74)

1. A Lanas F Sopena 2009 Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications Gastroenterol Clin North Am 38 2 333 352 19446262 10.1016/j.gtc.2009.03.007
2. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 6 417 429 12167685 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D (Pubitemid 34851835)
3. JR Korzenik DK Podolsky 2006 Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease Clin Gastroenterol Hepatol 4 2 157 159 16469674 10.1016/j.cgh.2005.11.007 (Pubitemid 43199684)
4. K Takeuchi S Smale P Premchand L Maiden R Sherwood B Thjodleifsson E Bjornsson I Bjarnason 2006 Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 4 2 196 202 16469680 10.1016/S1542-3565(05)00980-8 1:CAS:528:DC%2BD28Xit1Gqu7c%3D (Pubitemid 43199690)
5. S Generini G Fiori CM Matucci 2002 Therapy of spondyloarthropathy in inflammatory bowel disease Clin Exp Rheumatol 20 6 Suppl 28 S88 S94 12463455 1:STN:280:DC%2BD38jgtFOqtg%3D%3D
6. AM Meyer NN Ramzan RI Heigh JA Leighton 2006 Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs Dig Dis Sci 51 1 168 172 16416231 10.1007/s10620-006-3103-5 1:CAS:528: DC%2BD28XksVOqtQ%3D%3D (Pubitemid 43106356)
7. RN Dubois SB Abramson L Crofford RA Gupta LS Simon LB Van De Putte PE Lipsky 1998 Cyclooxygenase in biology and disease FASEB J 12 12 1063 1073 9737710 1:CAS:528:DyaK1cXlvFWntbY%3D
8. DS Rampton GE Sladen 1981 Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs Postgrad Med J 57 667 297 299 6117846 10.1136/pgmj.57.667.297 1:STN:280:DyaL38%2FlvFyluw%3D%3D
9. JF Fries SR Miller PW Spitz CA Williams HB Hubert DA Bloch 1989 Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use Gastroenterology 96 2 Pt 2 Suppl 647 655 2909442 1:STN:280: DyaL1M%2FnvV2hug%3D%3D
10. GF Bonner 2001 Exacerbation of inflammatory bowel disease associated with use of celecoxib Am J Gastroenterol 96 4 1306 1308 11316199 10.1111/j.1572-0241.2001.03730.x 1:STN:280:DC%2BD3MzntVWrsQ%3D%3D
11. JL Wallace 1997 Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years Gastroenterology 112 3 1000 1016 9041264 10.1053/gast.1997.v112.pm9041264 1:CAS:528:DyaK2sXhvFOlsLk%3D (Pubitemid 27113828)
12. P Emery H Zeidler TK Kvien M Guslandi R Naudin H Stead KM Verburg PC Isakson RC Hubbard GS Geis 1999 Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison Lancet 354 9196 2106 2111 10609815 10.1016/S0140-6736(99)02332-6 1:CAS:528: DC%2BD3cXnt1Crtg%3D%3D
13. JM Gornet Z Hassani R Modiglian M Lemann 2002 Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib Am J Gastroenterol 97 12 3209 3210 12492220 10.1111/j.1572-0241.2002.07142.x
14. K Kurahara T Matsumoto M Iida K Honda T Yao M Fujishima 2001 Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations Am J Gastroenterol 96 2 473 480 11232693 10.1111/j.1572-0241.2001. 03530.x 1:STN:280:DC%2BD3M7ot12nsA%3D%3D
15. GF Bonner M Walczak L Kitchen M Bayona 2000 Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease Am J Gastroenterol 95 8 1946 1948 10950040 10.1111/j.1572-0241.2000.02263.x 1:CAS:528:DC%2BD3cXmtl2qt7c%3D
16. GF Bonner A Fakhri SR Vennamaneni 2004 A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease Inflamm Bowel Dis 10 6 751 757 15626893 10.1097/00054725-200411000-00009 (Pubitemid 39545220)
17. E Rahme MA Marentette SX Kong J Lelorier 2002 Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population Arthritis Rheum 47 6 595 602 12522832 10.1002/art.10796 1:CAS:528:DC%2BD3sXjtVekuw%3D%3D
18. A Puspok HP Kiener G Oberhuber 2000 Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon Dis Colon Rectum 43 5 685 691 10826432 10.1007/BF02235589 1:STN:280: DC%2BD3c3osVKltw%3D%3D
19. I Bjarnason J Hayllar AJ Macpherson AS Russell 1993 Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans Gastroenterology 104 6 1832 1847 8500743 1:STN:280:DyaK3s3ntlajtA%3D%3D
20. JL Wallace W McKnight BK Reuter N Vergnolle 2000 NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2 Gastroenterology 119 3 706 714 10982765 10.1053/gast.2000.16510 1:CAS:528:DC%2BD3cXmslSrsr0%3D
21. RL Darling JJ Romero EJ Dial JK Akunda R Langenbach LM Lichtenberger 2004 The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice Gastroenterology 127 1 94 104 15236176 10.1053/j.gastro.2004.04.003 1:CAS:528: DC%2BD2cXmsVShsrg%3D (Pubitemid 38962278)
22. J Tibble K Teahon B Thjodleifsson A Roseth G Sigthorsson S Bridger R Foster R Sherwood M Fagerhol I Bjarnason 2000 A simple method for assessing intestinal inflammation in Crohn's disease Gut 47 4 506 513 10986210 10.1136/gut.47.4.506 1:CAS:528:DC%2BD3cXnsVCrurg%3D
23. AG Roseth PN Schmidt MK Fagerhol 1999 Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease Scand J Gastroenterol 34 1 50 54 10048733 10.1080/00365529950172835 1:STN:280: DyaK1M7ls1Ghsg%3D%3D (Pubitemid 29074787)
24. RD Newberry WF Stenson RG Lorenz 1999 Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen Nat Med 5 8 900 906 10426313 10.1038/11341 1:CAS:528:DyaK1MXltVyjsbo%3D (Pubitemid 29372416)
25. JM Evans AD McMahon FE Murray DG McDevitt TM MacDonald 1997 Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease Gut 40 5 619 622 9203940 1:CAS:528:DyaK2sXksFymtLw%3D
26. JB Felder BI Korelitz R Rajapakse S Schwarz AP Horatagis G Gleim 2000 Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study Am J Gastroenterol 95 8 1949 1954 10950041 10.1111/j.1572-0241.2000.02262.x 1:CAS:528:DC%2BD3cXmtl2qtL4%3D
27. GF Bonner A Fakhri SR Vennamaneni 2004 A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease Inflamm Bowel Dis 10 6 751 757 15626893 10.1097/00054725-200411000-00009 (Pubitemid 39545220)
28. M Guslandi 2006 Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction? World J Gastroenterol 12 10 1509 1510 16570341 1:CAS:528: DC%2BD28XksFCrsL0%3D
29. U Mahadevan EV Loftus Jr WJ Tremaine WJ Sandborn 2002 Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am J Gastroenterol 97 4 910 914 12008668 10.1111/j.1572-0241.2002.05608.x 1:CAS:528: DC%2BD38XktVKktrk%3D
30. WJ Sandborn WF Stenson J Brynskov RG Lorenz GM Steidle JL Robbins JD Kent BJ Bloom 2006 Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study Clin Gastroenterol Hepatol 4 2 203 211 16469681 10.1016/j.cgh.2005.12.002 1:CAS:528: DC%2BD28Xit1Kjsr4%3D (Pubitemid 43199691)
31. Y El Miedany S Youssef I Ahmed M El Gaafary 2006 The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases Am J Gastroenterol 101 2 311 317 16454836 10.1111/j.1572-0241.2006.00384.x 1:CAS:528:DC%2BD28XitFSgtrw%3D (Pubitemid 43381673)
32. W Reinisch W Miehsler C Dejaco M Harrer T Waldhoer C Lichtenberger H Vogelsang 2003 An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia Aliment Pharmacol Ther 17 11 1371 1380 12786631 10.1046/j.1365-2036. 2003.01596.x 1:CAS:528:DC%2BD3sXlslCisLc%3D (Pubitemid 36774144)
33. GM Wilcox AR Mattia 2005 Rofecoxib and inflammatory bowel disease: clinical and pathologic observations J Clin Gastroenterol 39 2 142 143 15681911
34. II Singer DW Kawka S Schloemann T Tessner T Riehl WF Stenson 1998 Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease Gastroenterology 115 297 306 9679035 10.1016/S0016-5085(98)70196-9 1:CAS:528:DyaK1cXltl2nsr0%3D (Pubitemid 28363422)
35. SA Weaver MP Russo KL Wright G Kolios C Jobin DA Robertson SG Ward 2001 Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells Gastroenterology 120 5 1117 1127 11266376 10.1053/gast.2001.23257 1:CAS:528:DC%2BD3MXjtVeqsLs%3D
36. L Biancone C Tosti A Geremia D Fina C Petruzziello S Emerenziani F Pallone 2004 Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial Aliment Pharmacol Ther 19 7 755 764 15043516 10.1111/j.1365-2036.2004.01907.x 1:CAS:528:DC%2BD2cXktVGnu7c%3D (Pubitemid 38496641)
37. J Goh D Wight M Parkes SJ Middleton JO Hunter 2002 Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: coprecipitants or coincidence? Am J Gastroenterol 97 4 1061 1062 12003391 10.1111/j.1572-0241. 2002.05631.x
38. JS Terhaar Sive Droste JB Tuynman HM Van Dullemen CJ Mulder 2006 Chemoprevention for colon cancer: new opportunities, fact or fiction? Scand J Gastroenterol Suppl 243 158 164 16782636 10.1080/00365520600664284 (Pubitemid 43941080)
39. G Thiefin L Beaugerie 2005 Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum Joint Bone Spine 72 4 286 294 16038840 10.1016/j.jbspin.2004.10.004 (Pubitemid 40994974)
40. KD Rainsford 1999 Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) Am J Med 107 6A 27S 35S 10628591 10.1016/S0002-9343(99)00365-4 1:CAS:528:DC%2BD3cXptlertA%3D%3D
41. JS Redfern M Feldman 1989 Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins Gastroenterology 96 2 Pt 2 Suppl 596 605 2642446 1:CAS:528:DyaL1MXhtFanurs%3D
42. K Tanaka S Suemasu T Ishihara Y Tasaka Y Arai T Mizushima 2009 Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis Eur J Pharmacol 603 1-3 120 132 19101538 10.1016/j.ejphar.2008.11.058 1:CAS:528:DC%2BD1MXhtFCjsLg%3D
43. JL Wallace 2001 Prostaglandin biology in inflammatory bowel disease Gastroenterol Clin North Am 30 4 971 980 11764538 10.1016/S0889-8553(05)70223-5 1:STN:280:DC%2BD38%2Fjsleltw%3D%3D (Pubitemid 33127198)
44. RN Dubois CF Eberhart CS Williams 1996 Introduction to eicosanoids and the gastroenteric tract Gastroenterol Clin North Am 25 2 267 277 9229572 10.1016/S0889-8553(05)70246-6 1:STN:280:DyaK2s%2FhtlChtQ%3D%3D (Pubitemid 26161468)
45. CR Atchison AB West A Balakumaran SJ Hargus LR Pohl DH Daiker JF Aronson WE Hoffmann BK Shipp M Treinen-Moslen 2000 Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats Gastroenterology 119 6 1537 1547 11113075 10.1053/gast.2000.20186 1:CAS:528:DC%2BD3MXhtlKntg%3D%3D
46. I Bjarnason K Takeuchi 2009 Intestinal permeability in the pathogenesis of NSAID-induced enteropathy J Gastroenterol 44 Suppl 19 23 29 19148789 10.1007/s00535-008-2266-6 1:CAS:528:DC%2BD1MXosVGqsQ%3D%3D
47. AZ Leite AM Sipahi AO Damiao AM Coelho AT Garcez MC Machado CA Buchpiguel FP Lopasso ML Lordello CL Agostinho AA Laudanna 2001 Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism Gut 48 2 163 167 11156635 10.1136/gut.48.2.163 1:CAS:528:DC%2BD3MXhtFKnsr0%3D (Pubitemid 32143727)
48. I Bjarnason G Zanelli T Smith P Prouse P Williams P Smethurst G Delacey MJ Gumpel AJ Levi 1987 Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans Gastroenterology 93 3 480 489 3609658 1:STN:280:DyaL2s3nslagsw%3D%3D
49. S Somasundaram S Rafi J Hayllar G Sigthorsson M Jacob AB Price A MacPherson T Mahmod D Scott JM Wrigglesworth I Bjarnason 1997 Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine Gut 41 3 344 353 9378390 1:CAS:528: DyaK2sXms1Shs78%3D
50. PJ Fortun CJ Hawkey 2007 Nonsteroidal antiinflammatory drugs and the small intestine Curr Opin Gastroenterol 23 2 134 141 17268241 1:CAS:528:DC%2BD2sXht1KktL4%3D
51. Y Hayashi H Yamamoto H Taguchi K Sunada T Miyata T Yano M Arashiro K Sugano 2009 Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease J Gastroenterol 44 Suppl 19 57 63 19148795 10.1007/s00535-008-2277-3
52. R Langenbach SG Morham HF Tiano CD Loftin BI Ghanayem PC Chulada JF Mahler CA Lee EH Goulding KD Kluckman HS Kim O Smithies 1995 Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration Cell 83 3 483 492 8521478 10.1016/0092-8674(95)90126-4 1:CAS:528:DyaK2MXpt1Olt78%3D
53. BJ Whittle 2004 Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors Eur J Pharmacol 500 1-3 427 439 15464050 10.1016/j.ejphar.2004.07.042 1:CAS:528:DC%2BD2cXotFCksrc%3D (Pubitemid 39304025)
54. S Smale J Tibble G Sigthorsson I Bjarnason 2001 Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine Best Pract Res Clin Gastroenterol 15 5 723 738 11566037 10.1053/bega.2001.0231 1:CAS:528:DC%2BD38Xhs1Klsw%3D%3D (Pubitemid 32982362)
55. NM Davies NM Skjodt 1999 Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug Clin Pharmacokinet 36 2 115 126 10092958 10.2165/00003088-199936020-00003 1:CAS:528:DyaK1MXitFCntLo%3D
56. JL Wallace 2008 Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88 4 1547 1565 18923189 10.1152/physrev.00004.2008 1:CAS:528:DC%2BD1cXhtlGgtbbM
57. B Cryer M Feldman 1998 Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs Am J Med 104 5 413 421 9626023 10.1016/S0002-9343(98)00091-6 1:CAS:528:DyaK1cXktVSjtbY%3D (Pubitemid 28274844)
58. BJ Whittle 2000 COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors Gut 47 3 320 325 10940262 10.1136/gut.47.3.320 1:CAS:528:DC%2BD3cXmsFOhtL8%3D (Pubitemid 30670819)
59. J O'Brien 2000 Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease Am J Gastroenterol 95 8 1859 1861 10950025 10.1111/j.1572-0241.2000.02241.x
60. CW Houchen WF Stenson 1999 Cyclooxygenase expression in intestinal epithelial cells Curr Opin Gastroenterol 15 2 97 99 17023926 10.1097/00001574-199903000-00001 1:CAS:528:DyaK1MXjt1Gjur4%3D (Pubitemid 29106114)
61. J Hendel OH Nielsen 1997 Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease Am J Gastroenterol 92 7 1170 1173 9219792 1:STN:280:DyaK2szmtlCquw%3D%3D
62. R Tsubouchi S Hayashi Y Aoi H Nishio S Terashima S Kato K Takeuchi 2006 Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats Digestion 74 2 91 100 17143008 10.1159/000097657 1:CAS:528:DC%2BD2sXhtFyit7k%3D (Pubitemid 46192733)
63. L Camacho-Barquero I Villegas JM Sanchez-Calvo E Talero S Sanchez-Fidalgo V Motilva dlL Alarcon 2007 Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis Int Immunopharmacol 7 3 333 342 17276891 10.1016/j.intimp.2006.11.006 1:CAS:528:DC%2BD2sXhtlSlt7Y%3D (Pubitemid 46186172)
64. TJ Williams 1979 Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation Br J Pharmacol 65 3 517 524 371730 1:CAS:528: DyaE1MXkvVert70%3D
65. G Cipolla F Crema S Sacco E Moro F De Ponti G Frigo 2002 Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives Pharmacol Res 46 1 1 6 12208114 10.1016/S1043-6618(02)00033-6 1:CAS:528:DC%2BD38Xms1Wms7g%3D (Pubitemid 35300786)
66. BK Reuter S Asfaha A Buret KA Sharkey JL Wallace 1996 Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2 J Clin Invest 98 9 2076 2085 8903327 10.1172/JCI119013 1:CAS:528:DyaK28XmvVequrY%3D
67. CA Lesch ER Kraus B Sanchez R Gilbertsen A Guglietta 1999 Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis Methods Find Exp Clin Pharmacol 21 2 99 104 10327390 10.1358/mf.1999.21.2.529236 1:CAS:528:DyaK1MXjtF2lsL4%3D
68. SA McCartney JA Mitchell PD Fairclough MJ Farthing TD Warner 1999 Selective COX-2 inhibitors and human inflammatory bowel disease Aliment Pharmacol Ther 13 8 1115 1117 10468690 10.1046/j.1365-2036.1999.00585.x 1:CAS:528:DyaK1MXlvFGnsb4%3D (Pubitemid 29374115)
69. G Sigthorsson R Crane T Simon M Hoover H Quan J Bolognese I Bjarnason 2000 COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin Gut 47 4 527 532 10986213 10.1136/gut.47.4.527 1:CAS:528:DC%2BD3cXnsVCrurc%3D
70. CJ Hawkey 2000 Nonsteroidal anti-inflammatory drug gastropathy Gastroenterology 119 2 521 535 10930388 10.1053/gast.2000.9561 1:CAS:528:DC%2BD3cXmtVWru70%3D
71. JR Vane 1971 Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 25 232 235 5284360 1:CAS:528:DyaE3MXltVyjur4%3D
72. G Sigthorsson M Jacob J Wrigglesworth S Somasundaram I Tavares R Foster A Roseth S Rafi T Mahmud R Simpson I Bjarnason 1998 Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat Scand J Gastroenterol 33 7 728 735 9712237 10.1080/00365529850171675 1:CAS:528:DyaK1cXltlejsLg%3D (Pubitemid 28358057)
73. J Page D Henry 2000 Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem Arch Intern Med 160 6 777 784 10737277 10.1001/archinte.160.6.777 1:CAS:528:DC%2BD3cXisVClsbc%3D
74. S Singh LA Graff CN Bernstein 2009 Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 104 5 1298 1313 19337242 10.1038/ajg.2009.15 1:CAS:528:DC%2BD1MXlsVelurs%3D